The ongoing TUXEDO-03 trial is specifically tailored to evaluate HER3-DXd in patients with breast cancer or NSCLC with active BM who have received at least one previous line of systemic therapy in the advanced setting, and in metastatic solid tumor patients who have either treatment-naïve LM or post-radiation recurrent LM who do not require immediate local treatment (Table 2) [59]. Here, ERBB3 is linked to non-small cell lung carcinoma.